Ekso Bionics Holdings Inc (NAS:EKSO)

Q1 2025 Ekso Bionics Holdings Inc Earnings Call Transcript

May 5, 2025 / 08:30 PM GMT

Release Date Price: $7.15 (-1.37%)

Transcript 10-Q8-K

Key Points

Positve

Ekso Bionics Holdings Inc (EKSO) reported a gross margin increase to 54% in Q1 2025, up from 52% in the same period of 2024, driven by cost savings in supply chain and reduced service costs.
The company has successfully engaged Pre-Healthcare to enhance market access services, which has been instrumental in the commercialization of over 300 medical devices.
Ekso Bionics Holdings Inc (EKSO) has developed a pipeline of more than 35 Medicare beneficiaries as potential candidates for their exo Indigo Personal device, marking a 37% increase from the previous quarter.
The company has strengthened its distribution network by partnering with National Seating and Mobility and Bionic P&O, which is expected to broaden access to their exoskeleton devices across the United States.
Ekso Bionics Holdings Inc (EKSO) reported an increase in cash and restricted cash to $8.1 million as of March 31, 2025, up from $6.5 million at the end of 2024, indicating improved financial stability.

Negative

Revenue for Q1 2025 decreased to $3.4 million from $3.8 million in the same period of 2024, primarily due to capital budget impacts on inpatient rehabilitation facilities.
The company reported a net loss of $2.9 million for Q1 2025, although this was an improvement from a $3.4 million loss in Q1 2024.
There is uncertainty regarding the capital budgets of inpatient rehabilitation facilities, which could impact future sales of Ekso Bionics Holdings Inc (EKSO)'s enterprise health products.
The company faces challenges in ensuring successful Medicare claim submissions due to the lack of a definitive set of criteria published by CMS or DME MACs.
Ekso Bionics Holdings Inc (EKSO) anticipates potential longer-term impacts on capital budgets due to economic uncertainties, which could affect their enterprise health business.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

EKSO.OQ - Ekso Bionics Holdings Inc
Q1 2025 Ekso Bionics Holdings Inc Earnings Call
May 05, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the XO Bionics first quarter of 2025 Financial Results conference call.

At this time, all participants are in a listen on mode, a question and answer session will follow the formal presentation.

If anyone should acquire operator assistance, please press 0 on your telephone keypad. As a reminder, this conference is being recorded. It is not my pleasure to introduce your host, Stephen Coler of Investor Relations.

Thank you. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and good

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.